

=> d his

(FILE 'HOME' ENTERED AT 10:34:55 ON 03 AUG 2000)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 10:35:17 ON 03 AUG 2000

L1 6635 S NEUROECTODERMAL(5A) (TUMOR OR CANCER OR NEOPLASIA)  
L2 68 S CHLOROTOXIN  
L3 0 S L1 AND L2  
L4 2389718 S TUMOR OR CANCER OR NEOPLASIA  
L5 26 S L2 AND L4  
L6 11 DUP REM L5 (15 DUPLICATES REMOVED)  
L7 52241 S FLUOSCHROME OR BIOTIN OR COLORIMETRIC(W)AGENT  
L8 176691 S FLUORESCENT(W)MICROSCOPY OR ELIZA OR ELISA OR FACS  
L9 226144 S L7 OR L8  
L10 0 S L9 AND L6  
L11 0 S L9 AND L2

=> d bib ab 1-11 16

✓  
L6 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2000 ACS  
AN 1999:330028 CAPLUS  
DN 130:335024  
TI Method of diagnosing and treating gliomas  
IN Ullrich, Nicole; Sontheimer, Harald W.  
PA UAB Research Foundation, USA  
SO U.S., 34 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 2

|      | PATENT NO.     | KIND | DATE     | APPLICATION NO. | DATE     |
|------|----------------|------|----------|-----------------|----------|
| PI   | US 5905027     | A    | 19990518 | US 1996-774154  | 19961226 |
|      | US 6028174     | A    | 20000222 | US 1997-980388  | 19971128 |
| PRAI | US 1995-9283   |      | 19951227 |                 |          |
|      | US 1996-774154 |      | 19961226 |                 |          |

AB The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived **tumor** cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.

RE.CNT 2

RE

- (1) Ullrich; Am J Physiol 1996, V270(5, pt 1), PC1511
- (2) Ullrich; Neuro Report 1996, V7(5), P1020 MEDLINE

L6 ANSWER 2 OF 11 MEDLINE DUPLICATE 1  
AN 1999337948 MEDLINE  
DN 99337948  
TI Modulation of glioma cell migration and invasion using Cl(-) and K(+) ion channel blockers.  
AU Soroceanu L; Manning T J Jr; Sontheimer H  
CS Department of Neurobiology, The University of Alabama at Birmingham,

Birmingham, Alabama 35294-0021, USA.  
 NC NS36692 (NINDS)  
 SO JOURNAL OF NEUROSCIENCE, (1999 Jul 15) 19 (14) 5911-54.  
 Journal code: JDF. ISSN: 0270-6474.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199910  
 EW 19991001  
 AB Human malignant gliomas are highly invasive **tumors**. Mechanisms that allow glioma cells to disseminate, migrating through the narrow extracellular brain spaces are poorly understood. We recently demonstrated expression of large voltage-dependent chloride (Cl(-)) currents, selectively expressed by human glioma cells in vitro and in situ (Ullrich et al., 1998). Currents are sensitive to several Cl(-) channel blockers, including **chlorotoxin** (Ctx), (Ullrich and Sontheimer; 1996; Ullrich et al; 1996), tetraethylammonium chloride (TEA), and tamoxifen (Ransom and Sontheimer, 1998). Using Transwell migration assays, we show that blockade of glioma Cl(-) channels specifically inhibits **tumor** cell migration in a dose-dependent manner. Ctx (5 microM), tamoxifen (10 microM), and TEA (1 mM) also prevented invasion of human glioma cells

into fetal rat brain aggregates, used as an in vitro model to assess **tumor** invasiveness. Anion replacement studies suggest that permeation of chloride ions through glioma chloride channel is obligatory for cell migration. Osmotically induced cell swelling and subsequent regulatory volume decrease (RVD) in cultured glioma cells were reversibly prevented by 1 mM TEA, 10 microM tamoxifen, and irreversibly blocked by 5 microM Ctx added to the hypotonic media. Cl(-) fluxes associated with adaptive shape changes elicited by cell swelling and RVD in glioma cells were inhibited by 5 microM Ctx, 10 microM tamoxifen, and 1 mM TEA, as determined using the Cl(-)-sensitive fluorescent dye 6-methoxy-N-ethylquinolinium iodide. Collectively, these data suggest that chloride channels in glioma cells may enable **tumor** invasiveness, presumably by facilitating cell shape and cell volume changes that are more conducive to migration and invasion.

J  
 L6 ANSWER 3 OF 11 MEDLINE DUPLICATE 2  
 AN 1999025865 MEDLINE  
 DN 99025865  
 TI Use of **chlorotoxin** for targeting of primary brain **tumors**

AU Soroceanu L; Gillespie Y; Khazaeli M B; Sontheimer H  
 CS Department of Neurobiology, University of Alabama at Birmingham, 35294, USA.

NC R01 NS 36692 (NINDS)  
 SO CANCER RESEARCH, (1998 Nov 1) 58 (21) 4871-9.  
 Journal code: CNF. ISSN: 0008-5472.

CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals; Cancer Journals  
 EM 199901  
 EW 19990104

AB Gliomas are primary brain **tumors** that arise from differentiated glial cells through a poorly understood malignant transformation.

Although glioma cells retain some genetic and antigenic features common to glial cells, they show a remarkable degree of antigenic heterogeneity and variable mutations in their genome. Glioma cells have recently been shown to express a glioma-specific chloride ion channel (GCC) that is sensitive to **chlorotoxin** (CTX), a small peptide purified from *Leiurus quinquestriatus* scorpion venom [N. Ullrich et al, Neuroreport, 7:

1020-1024, 1996; and N. Ullrich and H. Sontheimer, Am. J. Physiol. (Cell Physiol.), 270: C1511-C1521, 1996]. Using native and recombinant 125I-labeled CTX we show that toxin binding to glioma cells is specific and involves high affinity [dissociation constant ( $K_d$ )=4.2 nM] and low affinity ( $K_d$ =660 nM) binding sites. In radioreceptor assays, 125I-labeled CTX binds to a protein with  $M_r$ =72,000, presumably GCC or a receptor that modulates GCC activity. In vivo targeting and biodistribution experiments were obtained using 125I- and (131)I-labeled CTX injected into severe combined immunodeficient mice bearing xenografted gliomas. CTX selectively accumulated in the brain of tumor-bearing mice with calculated brain: muscle ratios of 36.4% of injected dose/g (ID/g), as compared to 12.4% ID/g in control animals. In the tumor-bearing severe combined immunodeficient mice, the vast majority of the brain-associated radioactivity was localized within the tumor (tumor :muscle ratio, 39.13% ID/g; contralateral brain:muscle ratio, 6.68%ID/g). Moreover, (131)I-labeled CTX distribution, visualized through in vivo imaging by gamma ray camera scans, demonstrates specific and persistent intratumoral localization of the radioactive ligand. Immunohistochemical studies using biotinylated and fluorescently tagged CTX show highly selective staining of glioma cells in vitro, in situ, and in sections of patient biopsies. Comparison tissues including normal human brain, kidney, and colon were consistently negative for CTX immunostaining. These data suggest that CTX and CTX-conjugated molecules may serve as glioma-specific markers with diagnostic and therapeutic potential.

L6 ANSWER 4 OF 11 MEDLINE DUPLICATE 3  
 AN 1998161360 MEDLINE  
 DN 98161360  
 TI Expression of voltage-activated chloride currents in acute slices of human gliomas.  
 AU Ullrich N; Bordey A; Gillespie G Y; Sontheimer H  
 CS Department of Neurobiology, University of Alabama at Birmingham, 35294, USA.  
 NC R01-NS31234 (NINDS)  
 R01-NS36692 (NINDS)  
 SO NEUROSCIENCE, (1998 Apr) 83 (4) 1161-73.  
 Journal code: NZR. ISSN: 0306-4522.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199806  
 EW 19980603  
 AB Using whole-cell patch-clamp recordings, we identified a novel voltage-activated chloride current that was selectively expressed in glioma cells from 23 patient biopsies. Chloride currents were identified in 64% of glioma cells studied in acute slices of nine patient biopsies. These derived from gliomas of various pathological grades. In addition, 98% of cells acutely isolated or in short-term culture from 23 patients diagnosed with gliomas showed chloride current expression. These currents, which we termed glioma chloride currents activated at potentials >45 mV, showed pronounced outward rectification, and were sensitive to bath application of the presumed Cl<sup>-</sup> channel specific peptide **chlorotoxin** (approximately 600 nM) derived from Leiurus scorpion venom. Interestingly, low grade tumours (e.g., pilocytic astrocytomas), containing more differentiated, astrocyte-like cells showed expression of glioma chloride currents in concert with voltage-activated sodium and potassium currents also seen in normal astrocytes. By contrast, high grade

tumours (e.g., glioblastoma multiforme) expressed almost exclusively chloride currents, suggesting a gradual loss of Na<sup>+</sup> currents and gain of Cl<sup>-</sup> currents with increasing pathological tumour grade. To expand on the observation that these chloride currents are glioma-specific, we introduced experimental tumours in scid mice by intracranial injection of D54MG glioma cells and subsequently recorded from tumour cells and adjacent normal glial cells in acute slices. We consistently observed expression of **chlorotoxin**-sensitive chloride channels in implanted glioma cells, but without evidence for expression of chloride channels in surrounding "normal" host glial cells, suggesting that these chloride channels are probably a glioma-specific feature. Finding of this novel glioma specific Cl<sup>-</sup> channel in gliomas in situ and it's selective binding of **chlorotoxin** may provide a way to identify or target glioma cells in the future.

J L6 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2000 ACS  
 AN 1997:505749 CAPLUS  
 DN 127:119322  
 TI Method of diagnosing and treating gliomas  
 IN Sontheimer, Harald W.; Ullrich, Nicole  
 PA UAB Research Foundation, USA  
 SO PCT Int. Appl., 81 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

|      | PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE     |
|------|--|------|----------|-----------------|----------|
| PI   | WO 9724619   | A1   | 19970710 | WO 1996-US20403 | 19961227 |
|      | W: AU, CA, JP  |      |          |                 |          |
|      | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,  |      |          |                 |          |
| SE   | CA 2249351   | AA   | 19970710 | CA 1996-2249351 | 19961227 |
|      | AU 9722399   | A1   | 19970728 | AU 1997-22399   | 19961227 |
|      | EP 953153  | A1   | 19991103 | EP 1996-946129  | 19961227 |
|      | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI  |      |          |                 |          |
| PRAI | US 1995-9283   |      | 19951227 |                 |          |
|      | WO 1996-US20403  |      | 19961227 |                 |          |
| AB   | The present invention relates generally to the fields of cell physiolo., neurol. and neuro-oncol. More specifically, the present invention relates to a novel method of detection of the membrane protein "glioma chloride channel" for use as a specific tumor marker for the diagnosis and treatment of gliomas and meningiomas. The invention describes the expression of this chloride conductance with unique properties that selectively characterizes tumor-derived cells of glial origin. Whole-cell patch-clamp techniques were used to characterize the biophys. and pharmacol. properties of chloride channels in primary cultures and acutely isolated cells from biopsies of human astrocytomas and established cell lines. |      |          |                 |          |

L6 ANSWER 6 OF 11 BIOSIS COPYRIGHT 2000 BIOSIS  
 AN 1997:535069 BIOSIS  
 DN PREV199799834272  
 TI Targeting of glioma cells using **chlorotoxin**, a scorpion venom peptide.  
 AU Soroceanu, L. (1); Gillespie, G. Y.; Khazaeli, M. B.; Sontheimer, H.  
 CS (1) Dep. Neurobiol., Univ. Ala. at Birmingham, Birmingham, AL USA  
 SO Society for Neuroscience Abstracts, (1997) Vol. 23, No. 1-2, pp. 2448.  
 Meeting Info.: 27th Annual Meeting of the Society for Neuroscience New Orleans, Louisiana, USA October 25-30, 1997  
 ISSN: 0190-5295.  
 DT Conference

LA English

L6 ANSWER 7 OF 11 SCISEARCH COPYRIGHT 2000 ISI (R)

AN 97:781387 SCISEARCH

GA The Genuine Article (R) Number: YB153

TI Cell cycle-dependent expression of a glioma-specific chloride current: proposed link to cytoskeletal changes

AU Ullrich N; Sontheimer H (Reprint)

CS UNIV ALABAMA, DEPT NEUROBIOL, 1719 6TH AVE S, CIRC RM 545, BIRMINGHAM, AL 35294 (Reprint); UNIV ALABAMA, DEPT NEUROBIOL, BIRMINGHAM, AL 35294

CYA USA

SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, (OCT 1997) Vol. 42, No. 4, pp. C1290-C1297.  
 Publisher: AMER PHYSIOLOGICAL SOC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814.  
 ISSN: 0363-6143.

DT Article; Journal

FS LIFE

LA English

REC Reference Count: 38

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB We recently demonstrated expression of a novel, glioma-specific Cl<sup>-</sup> current in glial-derived **tumor** cells (gliomas), including stable cell lines such as STTG1, derived from a human anaplastic astrocytoma. We used STTG1 cells to study whether glioma Cl<sup>-</sup> channel (GCC) activity is regulated during cell cycle progression. Cells were arrested in defined stages of cell cycle (G(0), G(1), G(1)/S, S, and M phases) using serum starvation, mevastatin, hydroxyurea, demecolcine, and cytosine beta-D-arabinofuranoside. Cell cycle arrest was confirmed by measuring [H-3]thymidine incorporation and by DNA flow cytometry. Using whole cell patch-clamp recordings, we demonstrate differential changes in GCC activity after cell proliferation and cell cycle progression was selectively altered; specifically, channel expression was low in serum-starved, G(0)-arrested cells, increased significantly in early G(1), decreased during S phase, and increased after arrest in M phase. Although the link between the cell cycle and GCC activity is not yet clear, we speculate that GCCs are linked to the cytoskeleton and that cytoskeletal rearrangements associated with cell division lead to the observed changes in channel activity. Consistent with this hypothesis, we demonstrate the activation of GCC by disruption of F-actin using cytochalasin D or osmotic cell swelling.

L6 ANSWER 8 OF 11 MEDLINE DUPLICATE 4

AN 96226464 MEDLINE

DN 96226464

TI Biophysical and pharmacological characterization of chloride currents in human astrocytoma cells.

AU Ullrich N; Sontheimer H

CS Neurobiology Research Center, University of Alabama at Birmingham 35294, USA.

NC R01-NS-31234 (NINDS)  
 P50-HD-32901 (NICHD)

SO AMERICAN JOURNAL OF PHYSIOLOGY, (1996 May) 270 (5 Pt 1) C1511-21.  
 Journal code: 3U8. ISSN: 0002-9513.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199702

EW 19970204

AB Expression of voltage-activated ion channels was studied in primary cultures from seven freshly resected human primary brain **tumors**

and in an established human astrocytoma cell line, STTG1. Astrocytoma cells consistently expressed voltage-dependent outwardly rectifying currents. Currents activated at potentials > 45 mV and showed outward transients on termination of voltage steps. Currents reversed at the Cl<sup>-</sup> equilibrium potential, suggesting that they were largely carried by Cl<sup>-</sup>. Altering extracellular K<sup>+</sup> or Na<sup>+</sup> concentration did not alter currents; neither did replacement of intracellular K<sup>+</sup> by Cs<sup>+</sup> or intracellular Na<sup>+</sup>

by

N-methyl-D-glucosamine. Anion-substitution experiments suggest the following permeability sequence, determined from shifts in tail current reversal potential: I<sup>-</sup> > NO<sub>3</sub><sup>-</sup> > Br<sup>-</sup> > Cl<sup>-</sup> > acetate > isethionate > F<sup>-</sup> > glutamate. Currents were sensitive to the Cl<sup>-</sup> channel blockers **chlorotoxin**, 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS), and 4,4'-dinitrostilbene-2,2'-disulfonic acid (DNDS), with **chlorotoxin** being most effective, yielding > 80% block at 590 nM. DIDS (100 µM) and DNDS (100 µM) reduced currents by 33.5 and 38.2%, respectively. Currents were also sensitive to Zn<sup>2+</sup> (100 µM,

47%

block) and Cd<sup>2+</sup> (25 µM, 42% block). Reducing extracellular Ca<sup>2+</sup> concentration decreased outward currents by 58% and almost completely eliminated transients, suggesting that Cl<sup>-</sup> currents are Ca<sup>2+</sup> dependent.

Cl

channel block resulted in altered cell proliferation as determined by [<sup>3</sup>H]thymidine incorporation, suggesting that these channels may be involved in astrocytoma growth control.

L6 ANSWER 9 OF 11 SCISEARCH COPYRIGHT 2000 ISI (R)  
AN 96:372248 SCISEARCH  
GA The Genuine Article (R) Number: UJ814  
TI BIOPHYSICAL AND PHARMACOLOGICAL CHARACTERIZATION OF CHLORIDE CURRENTS IN HUMAN ASTROCYTOMA-CELLS  
AU ULLRICH N; SONTHEIMER H (Reprint)  
CS UNIV ALABAMA, NEUROBIOL RES CTR, 1719 6TH AVE S, CIRC RM 545, BIRMINGHAM, AL, 35294 (Reprint); UNIV ALABAMA, NEUROBIOL RES CTR, BIRMINGHAM, AL, 35294  
CYA USA  
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, (MAY 1996) Vol. 39, No. 5,  
pp. C1511-C1521.  
ISSN: 0363-6143.  
DT Article; Journal  
FS LIFE  
LA ENGLISH  
REC Reference Count: 41  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB Expression of voltage-activated ion channels was studied in primary cultures from seven freshly resected human primary brain **tumors** and in an established human astrocytoma cell line, STTG1. Astrocytoma cells consistently expressed voltage-dependent outwardly rectifying currents. Currents activated at potentials >45 mV and showed outward transients on termination of voltage steps. Currents reversed at the Cl<sup>-</sup> equilibrium potential, suggesting that they were largely carried by Cl<sup>-</sup>. Altering extracellular K<sup>+</sup> or Na<sup>+</sup> concentration did not alter currents; neither did replacement of intracellular K<sup>+</sup> by Cs<sup>+</sup> or intracellular Na<sup>+</sup>

by

N-methyl-D-glucosamine. Anion-substitution experiments suggest the following permeability sequence, determined from shifts in tail current reversal potential: I<sup>-</sup> > NO<sub>3</sub><sup>-</sup> > Br<sup>-</sup> > Cl<sup>-</sup> > acetate > isethionate > F<sup>-</sup> > glutamate. Currents were sensitive to the Cl<sup>-</sup> channel blockers **chlorotoxin**, 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS), and 4,4'-dinitrostilbene-2,2'-disulfonic acid (DNDS), with **chlorotoxin** being most effective, yielding >80% block at 590 nM. DIDS (100 µM) and DNDS (100 µM) reduced currents by 33.5 and 38.2%, respectively. Currents were also sensitive to Zn<sup>2+</sup> (100 µM, 47% block) and Cd<sup>2+</sup> (25 µM, 42% block). Reducing extracellular Ca<sup>2+</sup> concentration

decreased outward currents by 58% and almost completely eliminated transients, suggesting that Cl<sup>-</sup> currents are Ca<sup>2+</sup> dependent. Cl<sup>-</sup> channel block resulted in altered cell proliferation as determined by [H-3]thymidine incorporation, suggesting that these channels may be involved in astrocytoma growth control.

L6 ANSWER 10 OF 11 MEDLINE  
AN 96396940 MEDLINE  
DN 96396940  
TI Human astrocytoma cells express a unique chloride current.  
AU Ullrich N; Gillespie G Y; Sontheimer H  
CS Neurobiology Research Center, University of Alabama at Birmingham 35294, USA.  
NC RO-1 NS31234 (NINDS)  
P50 HD32901 (NICHD)  
P20 NS31096 (NINDS)  
SO NEUROREPORT, (1996 Apr 10) 7 (5) 1020-4.  
Journal code: A6M. ISSN: 0959-4965.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199702  
EW 19970204  
AB Human astrocytoma cells were studied using whole-cell patch-clamp recording. Voltage-dependent outwardly-rectifying anion currents were identified in primary cultures of six freshly resected human brain tumors and in seven established anaplastic astrocytoma/glioblastoma cell lines (U251MG, CH235MG, U373MG, U105MG, D54MG, SK-MG-1, and STTG1). Anion currents were not observed in normal, non-neoplastic glial cells, nor in human tumor-derived cells of non-glial origin (melanoma, breast cancer, neuroblastoma, rhabdomyosarcoma). Currents activated at potentials > 50 mV and showed large transients upon termination of voltage steps. Currents reversed at the predicted equilibrium potential for chloride ions and could also be recorded when Cl<sup>-</sup> was replaced by F<sup>-</sup>, Br<sup>-</sup> or I<sup>-</sup>. Currents were inhibited by the Cl<sup>-</sup> channel blockers chlorotoxin, DIDS, and DNDS. These Cl<sup>-</sup> currents may play a role in the growth control of astrocytoma cells.

L6 ANSWER 11 OF 11 MEDLINE  
AN 96352227 MEDLINE  
DN 96352227  
TI Human astrocytoma cells express a unique chloride current.  
AU Ullrich N; Gillespie G Y; Sontheimer H  
CS Interdepartmental Neuroscience Program, Yale University School of Medicine, New Haven, CT 06510, USA.  
NC RO-1 NS31234 (NINDS)  
P50 HD32901 (NICHD)  
P20 NS31096 (NINDS)  
SO NEUROREPORT, (1995 Dec 29) 7 (1) 343-7.  
Journal code: A6M. ISSN: 0959-4965.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199612  
AB Human astrocytoma cells were studied using whole-cell patch-clamp recording. Voltage-dependent outwardly-rectifying anion currents were identified in primary cultures of six freshly resected human brain tumors and in seven established anaplastic astrocytoma/glioblastoma cell lines (U251MG, CH235MG, U373MG, U105MG, D54MG, SK-MG-1, and STTG1). Anion currents were not observed in normal, non-neoplastic glial cells, nor in human tumor-derived cells of non-glial origin (melanoma, breast cancer, neuroblastoma, rhabdomyosarcoma). Currents activated at potentials > 50 mV and showed

large transients upon termination of voltage steps. Currents reversed at the predicted equilibrium potential for chloride ions and could also be recorded when Cl<sup>-</sup> was replaced by F<sup>-</sup>, Br<sup>-</sup> or I<sup>-</sup>. Currents were inhibited by the Cl<sup>-</sup> channel blockers **chlorotoxin**, DIDS, and DNDS. These Cl<sup>-</sup> currents may play a role in the growth control of astrocytoma cells.

=>

=>